DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients

Dapagliflozin cut the relative incidence of new-onset type 2 diabetes by one third in patients with heart failure in the multicenter trial.Medscape Medical News

Source: Medscape Internal Medicine Headlines - June 16, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news